Simplify Logo

Full-Time

Process Engineer

Formulation Development

Confirmed live in the last 24 hours

Editas Medicine

Editas Medicine

201-500 employees

Develops gene editing treatments using CRISPR

Hardware
Biotechnology
Healthcare

Mid, Senior

Cambridge, MA, USA

Category
Computational Biology
Genomics
Biology & Biotech
Requirements
  • Bachelor’s experience in Chemical Engineering, Biomedical Engineering, Chemistry, Pharmaceutical Sciences, or related discipline with 6+ years of relevant experience or Master’s with 4+ years of experience.
  • Strong technical expertise and meaningful hands-on experience in mRNA/LNP formulation development, scale-up and/or manufacturing in a drug development setting are required.
  • Proficient UFDF/Dialysis operation skills with solid understanding of scale-up principles.
  • Proficient verbal communication and technical writing skills.
Responsibilities
  • Lead or support experiments for RNP, mRNA/LNP manufacturing process definition, scale-down model qualification, process characterization/optimization and scale-up to meet clinical and commercial material demand
  • Support the generation of representative materials for analytical method development and toxicology studies
  • Support technology transfer of mRNA/LNP manufacturing process to internal or external manufacturing facilities for clinical and commercial manufacturing, in collaboration with Manufacturing and Quality teams
  • Collaborate with AD to generate data for formulation studies, stability studies, and characterization of drug substance and/or drug product
  • Provide technical support for engineering and cGMP manufacturing campaigns (e.g. batch record review, change control management, deviation investigation, etc) in collaboration with other line functions (e.g., Manufacturing Sciences & Technology), as needed
  • Document all experimental work, supporting information, and data in an electronic lab notebook (eLN) in a timely manner
  • Compile and present data, and assist in authoring and reviewing of batch records, work instructions, protocols, plans, technical reports, SOPs, and may contribute to regulatory document drafting and review
  • Cross-train personnel on processes, and provide guidance to junior team members, as required
  • Maintain abreast latest industry trends for RNP, LNP and nucleic acid-based process and product knowledge
  • Contribute to equipment procurement, setup and training
  • Other responsibilities as required.

Editas Medicine focuses on gene editing using CRISPR technology, which allows for precise modifications to DNA in cells. This technique has the potential to correct genetic defects that lead to various diseases. The company is engaged in the entire process of drug development, from discovering new treatments to manufacturing and bringing them to market. Editas Medicine aims to create long-lasting therapies that can greatly enhance the quality of life for patients suffering from serious illnesses. Unlike many competitors, Editas has a diverse pipeline of experimental medicines and actively shares clinical data to keep stakeholders informed. The ultimate goal is to provide effective treatments for patients worldwide, while also generating revenue through partnerships and commercialization of their genomic medicines.

Company Stage

IPO

Total Funding

$884.6M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

14%

1 year growth

22%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful clinical trials, like the EDIT-101 for Leber Congenital Amaurosis, demonstrate the potential for groundbreaking treatments.
  • The extension of collaborations with major pharmaceutical companies like Bristol Myers Squibb indicates strong industry validation and potential for future growth.
  • Recent investments, such as the $23.36 million from Marshall Wace LLP, reflect confidence in the company's innovative approach and financial stability.

What critics are saying

  • The highly competitive field of gene editing requires continuous innovation to maintain a leading position.
  • Regulatory hurdles and ethical concerns surrounding gene editing could delay or impede the commercialization of treatments.

What makes Editas Medicine unique

  • Editas Medicine leverages CRISPR technology to develop transformative treatments for serious diseases, setting it apart from traditional biotech firms.
  • The company's comprehensive approach, from discovery to commercialization, ensures a streamlined process for bringing genomic medicines to market.
  • Editas Medicine's strategic partnerships, such as with Bristol Myers Squibb, enhance its capabilities in developing gene-edited therapies.